CCL20

Across TCGA pan-cancer cohorts, CCL20 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CCL20’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CCL20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CCL20 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

THCA, COAD, and KIRC are the cancer types where CCL20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCL20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	+1.804	<.001	11	view →
COAD	All	III,IV	+1.686	<.001	10	view →
KIRC	Male	All	+2.808	<.001	9	view →
LIHC	All	III,IV	+3.228	<.001	8	view →
HNSC	All	All	+1.225	.002	7	view →
LUAD	Female	II,III,IV	+2.815	<.001	5	view →
KICH	Female	All	−1.955	<.001	5	view →
STAD	All	All	+1.846	.004	4	view →
BRCA	All	All	+0.631	<.001	4	view →
CHOL	Male	All	+4.195	<.001	2	view →
UCEC	All	All	+1.128	.033	2	view →
ESCA	All	All	+3.306	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CCL20–THCA

Open the THCA breakdown →